Daiichi Sankyo Company, Limited
JPX: 4568.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Hiroyuki Okuzawa
- Employees
- 18,726
- Headquarters
- Tokyo, Japan
- IPO year
- 2000
- Market cap
- ¥4.8T
- Website
- https://www.daiichisankyo.com
Loading 4568…
Loading profile data…Frequently asked questions about 4568
What does Daiichi Sankyo Company, Limited (4568.T) do?
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide...
Where does 4568.T trade?
Daiichi Sankyo Company, Limited (4568.T) trades on the Tokyo Stock Exchange.
What sector is 4568.T in?
Daiichi Sankyo Company, Limited (4568.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Daiichi Sankyo Company, Limited?
Hiroyuki Okuzawa is the chief executive officer of Daiichi Sankyo Company, Limited (4568.T).
Where is Daiichi Sankyo Company, Limited headquartered?
Daiichi Sankyo Company, Limited is headquartered in Japan.
Does 4568.T pay a dividend?
Yes — Daiichi Sankyo Company, Limited (4568.T) paid a trailing twelve-month dividend of JPY 78.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4568.T go public?
Daiichi Sankyo Company, Limited (4568.T) completed its initial public offering in 2000.